SE9600072D0 - New oral formulation of two active ingredients II - Google Patents

New oral formulation of two active ingredients II

Info

Publication number
SE9600072D0
SE9600072D0 SE9600072A SE9600072A SE9600072D0 SE 9600072 D0 SE9600072 D0 SE 9600072D0 SE 9600072 A SE9600072 A SE 9600072A SE 9600072 A SE9600072 A SE 9600072A SE 9600072 D0 SE9600072 D0 SE 9600072D0
Authority
SE
Sweden
Prior art keywords
pct
sec
fixed formulation
active ingredients
oral formulation
Prior art date
Application number
SE9600072A
Other languages
English (en)
Swedish (sv)
Inventor
Helene Depui
Agneta Hallgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9600072A priority Critical patent/SE9600072D0/xx
Publication of SE9600072D0 publication Critical patent/SE9600072D0/xx
Priority to KR1019970706235A priority patent/KR100486057B1/ko
Priority to DK96944725T priority patent/DK0814840T3/da
Priority to US08/750,936 priority patent/US6132771A/en
Priority to MX9706769A priority patent/MX9706769A/es
Priority to PCT/SE1996/001736 priority patent/WO1997025065A1/en
Priority to PL96322176A priority patent/PL322176A1/xx
Priority to AT96944725T priority patent/ATE228010T1/de
Priority to BR9607344A priority patent/BR9607344A/pt
Priority to PT96944725T priority patent/PT814840E/pt
Priority to NZ325976A priority patent/NZ325976A/xx
Priority to AU13240/97A priority patent/AU712572B2/en
Priority to EP96944725A priority patent/EP0814840B1/en
Priority to CNB96193607XA priority patent/CN1142792C/zh
Priority to EE9700195A priority patent/EE9700195A/xx
Priority to SK1170-97A priority patent/SK117097A3/sk
Priority to IL12165296A priority patent/IL121652A/en
Priority to ES96944725T priority patent/ES2185816T3/es
Priority to TR97/00917T priority patent/TR199700917T1/xx
Priority to HU9904094A priority patent/HUP9904094A3/hu
Priority to CZ972808A priority patent/CZ280897A3/cs
Priority to CA002214033A priority patent/CA2214033C/en
Priority to DE69624910T priority patent/DE69624910T2/de
Priority to JP9525130A priority patent/JPH11501949A/ja
Priority to ARP960105898A priority patent/AR008750A1/es
Priority to ZA9610938A priority patent/ZA9610938B/xx
Priority to IDP970026A priority patent/ID18383A/id
Priority to IS4550A priority patent/IS4550A/is
Priority to NO19974070A priority patent/NO316425B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9600072A 1996-01-08 1996-01-08 New oral formulation of two active ingredients II SE9600072D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9600072A SE9600072D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients II
JP9525130A JPH11501949A (ja) 1996-01-08 1996-12-20 プロトンポンプ抑制剤およびプロキネティック剤を含有する経口用医薬剤形
EP96944725A EP0814840B1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
EE9700195A EE9700195A (et) 1996-01-08 1996-12-20 Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
US08/750,936 US6132771A (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
MX9706769A MX9706769A (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
PCT/SE1996/001736 WO1997025065A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
PL96322176A PL322176A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutic administration forms containing the protonic pump inhibitor and a prokinetic agent
AT96944725T ATE228010T1 (de) 1996-01-08 1996-12-20 Orale pharmazeutische dosierungsformen die einen protonenpumpeninhibitor und ein prokinetisches mittel enthalten
BR9607344A BR9607344A (pt) 1996-01-08 1996-12-20 Formas de dosagem farmacéutica oral e de tablete processos para preparar a forma de dosagem fixada e para tratar distúrbios associados ás doenças de refluxo gastro-esofrágico e uso da forma de dosagem
PT96944725T PT814840E (pt) 1996-01-08 1996-12-20 Formas de dosagem farmaceutica orais compreendendo um inibidor de uma bomba de protoes e um agente procinetico
NZ325976A NZ325976A (en) 1996-01-08 1996-12-20 Compositions comprising an enteric coated acid susceptible proton pump inhibitor and a prokinetic agent
AU13240/97A AU712572B2 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
KR1019970706235A KR100486057B1 (ko) 1996-01-08 1996-12-20 양성자펌프억제제및프로키네틱제함유경구제약제형
CNB96193607XA CN1142792C (zh) 1996-01-08 1996-12-20 含质子泵抑制剂和促动力剂的口服药物剂型
DK96944725T DK0814840T3 (da) 1996-01-08 1996-12-20 Orale farmaceutiske doseringsformer, der omfatter en protonpumpeinhibitor og et prokinetisk middel
SK1170-97A SK117097A3 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
IL12165296A IL121652A (en) 1996-01-08 1996-12-20 Pharmaceutical dosage forms for oral administration that include a proton pump inhibitor and a prokinetic substance
ES96944725T ES2185816T3 (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
TR97/00917T TR199700917T1 (xx) 1996-01-08 1996-12-20 Oral farmas�tik dozaj formlar�.
HU9904094A HUP9904094A3 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
CZ972808A CZ280897A3 (cs) 1996-01-08 1996-12-20 Orální farmaceutické lékové formy obsahující inhibitor protonové pumpy a prokinetické činidlo
CA002214033A CA2214033C (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
DE69624910T DE69624910T2 (de) 1996-01-08 1996-12-20 Orale pharmazeutische dosierungsformen die einen protonenpumpeninhibitor und ein prokinetisches mittel enthalten
ARP960105898A AR008750A1 (es) 1996-01-08 1996-12-26 Formas de dosis farmaceuticas orales que comprende un inhibidor de bombeo protonico y un agente procinetico, proceso para su fabricacion y uso de dichasformas para la fabricacion de medicamentos
ZA9610938A ZA9610938B (en) 1996-01-08 1996-12-30 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
IDP970026A ID18383A (id) 1996-01-08 1997-01-08 Dosis farmasi oral yang mengandung penghambat pompa proton dan zat prokinetik
IS4550A IS4550A (is) 1996-01-08 1997-08-21 Lyf í formi skammta til inntöku um munn sem inniheldur prótónupumpublokkara og prókínetískt efni
NO19974070A NO316425B1 (no) 1996-01-08 1997-09-04 Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600072A SE9600072D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients II

Publications (1)

Publication Number Publication Date
SE9600072D0 true SE9600072D0 (sv) 1996-01-08

Family

ID=20400970

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600072A SE9600072D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients II

Country Status (29)

Country Link
US (1) US6132771A (https=)
EP (1) EP0814840B1 (https=)
JP (1) JPH11501949A (https=)
KR (1) KR100486057B1 (https=)
CN (1) CN1142792C (https=)
AR (1) AR008750A1 (https=)
AT (1) ATE228010T1 (https=)
AU (1) AU712572B2 (https=)
BR (1) BR9607344A (https=)
CA (1) CA2214033C (https=)
CZ (1) CZ280897A3 (https=)
DE (1) DE69624910T2 (https=)
DK (1) DK0814840T3 (https=)
EE (1) EE9700195A (https=)
ES (1) ES2185816T3 (https=)
HU (1) HUP9904094A3 (https=)
ID (1) ID18383A (https=)
IL (1) IL121652A (https=)
IS (1) IS4550A (https=)
MX (1) MX9706769A (https=)
NO (1) NO316425B1 (https=)
NZ (1) NZ325976A (https=)
PL (1) PL322176A1 (https=)
PT (1) PT814840E (https=)
SE (1) SE9600072D0 (https=)
SK (1) SK117097A3 (https=)
TR (1) TR199700917T1 (https=)
WO (1) WO1997025065A1 (https=)
ZA (1) ZA9610938B (https=)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK2263660T3 (en) 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
ATE291418T1 (de) 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
CA2366768C (en) * 1999-04-01 2005-05-24 Wm. Wrigley Jr. Company Long flavor duration releasing structures for chewing gum
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
US6623757B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
CN1187052C (zh) 2000-03-30 2005-02-02 布里斯托尔-迈尔斯斯奎布公司 含有司他夫定(stavudine)的持续释放微球
US20040146554A1 (en) * 2000-07-15 2004-07-29 Sharma Virender K. Method for the administration of acid-labile drugs
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
ES2426723T3 (es) 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
JP2006282677A (ja) * 2001-10-17 2006-10-19 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
BR8300543U (pt) * 2003-04-09 2004-11-23 Medley S A Ind Farmaceutica Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte dos pacientes
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2533358C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
US8758820B2 (en) 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
BRPI0414046A (pt) * 2003-08-29 2006-10-24 Dynogen Pharmaceuticals Inc método de tratamento de um distúrbio de motilidade gastrintestinal, de tratamento de "gerd", de "gerd" noturno, composição farmacêutica, kit que compreende um composto e método para aumentar a motilidade esofágica em um paciente
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
RS20050796A (sr) * 2004-01-06 2007-08-03 Panacea Biotec Ltd., Farmaceutske smeše koje sadrže inhibitor protonske pumpe i prokinetičko sredstvo
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
WO2006011638A1 (ja) * 2004-07-28 2006-02-02 Dainippon Sumitomo Pharma Co., Ltd. 複数の被覆層を有するフィルムコーティング錠
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
KR20080096779A (ko) * 2006-01-20 2008-11-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 필름 코팅정
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2398470A4 (en) * 2009-02-23 2013-03-06 Aptalis Pharmatech Inc CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR
WO2010150219A1 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
AU2010321874A1 (en) * 2009-11-20 2012-06-21 Handa Pharmaceuticals, Llc Oral formulation for dexlansoprazole
ES2702753T3 (es) 2010-01-05 2019-03-05 Microdose Therapeutx Inc Dispositivo de inhalación
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
WO2011126327A2 (en) * 2010-04-09 2011-10-13 Hyundai Pharm Co., Ltd. Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
WO2011136750A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Pharmaceutical compositions inducing synergistic effect
BRPI1103093A2 (pt) * 2011-06-03 2013-07-02 Eurofarma Laboratarios Ltda composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN105142618A (zh) * 2013-03-15 2015-12-09 韩国联合制药株式会社 提供药理及临床效应的莫沙必利每日单次施用缓释制剂
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108289849A (zh) * 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102034694B1 (ko) * 2017-12-14 2019-10-22 한국유나이티드제약 주식회사 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제
WO2024224407A1 (en) * 2023-04-28 2024-10-31 Akums Drugs & Pharmaceuticals Limited Multi-layer pellet formulation and process of preparation thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) * 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
EP0653935B1 (en) * 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
EP0707492A1 (en) * 1993-07-06 1996-04-24 Merck & Co. Inc. H 2? antagonist-gastrointestinal motility agent combinations
JP3017906B2 (ja) * 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
WO1995010264A1 (en) * 1993-10-12 1995-04-20 Tokyo Tanabe Company Limited Tablet containing enteric granules
GB2285989A (en) * 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II

Also Published As

Publication number Publication date
NO974070L (no) 1997-10-06
IL121652A0 (en) 1998-02-08
HUP9904094A3 (en) 2002-03-28
DE69624910D1 (de) 2003-01-02
EP0814840B1 (en) 2002-11-20
ATE228010T1 (de) 2002-12-15
DK0814840T3 (da) 2003-02-24
US6132771A (en) 2000-10-17
NO316425B1 (no) 2004-01-26
KR100486057B1 (ko) 2005-09-08
EP0814840A1 (en) 1998-01-07
KR19980702828A (ko) 1998-08-05
AU1324097A (en) 1997-08-01
NZ325976A (en) 1999-02-25
AR008750A1 (es) 2000-02-23
HUP9904094A2 (hu) 2000-06-28
JPH11501949A (ja) 1999-02-16
PT814840E (pt) 2003-04-30
CA2214033C (en) 2006-01-10
WO1997025065A1 (en) 1997-07-17
ZA9610938B (en) 1997-07-08
IL121652A (en) 2002-03-10
EE9700195A (et) 1998-02-16
MX9706769A (es) 1997-11-29
SK117097A3 (en) 1998-06-03
BR9607344A (pt) 1997-12-30
ES2185816T3 (es) 2003-05-01
CN1183049A (zh) 1998-05-27
CA2214033A1 (en) 1997-07-17
CZ280897A3 (cs) 1998-04-15
AU712572B2 (en) 1999-11-11
ID18383A (id) 1998-04-02
TR199700917T1 (xx) 1997-11-21
PL322176A1 (en) 1998-01-19
DE69624910T2 (de) 2003-09-04
CN1142792C (zh) 2004-03-24
IS4550A (is) 1997-08-21
NO974070D0 (no) 1997-09-04

Similar Documents

Publication Publication Date Title
SE9600072D0 (sv) New oral formulation of two active ingredients II
SE9500422D0 (sv) New oral pharmaceutical dosage forms
SE9600070D0 (sv) New oral pharmaceutical dosage forms
MX9706785A (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
SE9600073L (sv) Doseringsform innehållande en mångfald enheter
SE9702533D0 (sv) New oral formulation
DE69636104D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern
NO960949L (no) Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
MX9600857A (es) Forma de dosificacion i en tabletas, con unidades multiples.
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
SE9700885D0 (sv) New pharmaceutical formulation
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
FR2718020B1 (fr) Composition galénique mucoadhésive hétérofonctionnelle.
SE9504267D0 (sv) New therapeutic use
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
DK1553943T3 (da) Anvendelse af tenatoprazol til behandling af gastroösofageal refluks
AR025498A1 (es) Una nueva asociacion farmaceutica que presenta un efecto analgesico
BR0101880A (pt) Uma nova composição farmacêutica
JO1881B1 (en) Formula II for multi unit disc calibration
NO976042L (no) Peptid som inhiberer ökning av triglyceridnivå i blod, og inhibitor av ökning av triglyceridnivå i blod inneholdende nevnte peptid som aktiv bestanddel
TH22304A (th) สารเตรียมทางเภสัชกรรมแบบหลายหน่วยที่มีสารยัยยั้งปั๊มโปรตอน